Nestin: A biomarker of aggressive uterine cancers

Abstract

High nestin was more common in UCs with aggressive features and poor outcome. Nestin may represent a predictive biomarker for treatment selection for patients previously considered to be lower risk and a candidate for no or radiation-based adjuvant therapy, and compliment ER/PR testing.

Laparoscopic Surgery for Large Ovarian Cysts-Review

“…The accuracy of predicting risk of disease progression within 5 years increased to 0.8 by combining nestin with tumor stage and type of uterine cancer. The addition of other biomarkers including ER, PR, and p53 to nestin, stage, and type of uterine cancer did not increase predictive accuracy further and in fact accuracy dropped below 63% [19].…”

“…High vs. low IHC expression of nestin indicated worse PFS in the subset of patients who either did not receive adjuvant therapy or who had adjuvant radiation only, but not in the patient treated with chemotherapy or chemoradiation [19].…”

“…In contrast, nestin expression was directly associated with tumor protein 53 (p53) which is more common in high risk, type II endometrial cancer [19].…”

“…The relationship between nestin and clinical outcomes was independent of stage, lymphovascular space invasion (LVSI) or risk categorization [19].…”

“…Advanced stage cancers and those with LVSI were twice as likely to exhibit high tumor staining for nestin. Patients with higher risk disease (grade 3 disease or nonendometrioid cell type) were 5 times more likely to exhibit high IHC tumor nestin expression [19].…”